arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Oncology Institute, Inc.

TOI

$5.12 0.00 (0.00%) at close

7 Visible periods

31 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Moderately Bearish

auto_awesome

Analytical Summary

Oncology Institute, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $473.0M

Dividend Yield —

Revenue Growth 27.8% ↗

Op. Margin -7.2% ↗

ROIC -58.4% ↗

FCF / Share $-0.30 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity -4.92

info Valuation on last close. End-of-day price, Aug 3, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$502.73M

↑ +27.8% —

Net Income Profit after all expenses

$-60.61M

↑ +6.3% —

Operating Margin Operating profit as % of sales

-7.2%

↑ +53.0% 18th

FCF / Share Free cash flow per share

$-0.30

↑ +25.6% —

Long-Term Debt Long-term obligations

$77.40M

↓ -16.9% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	27.8% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+456%)	21.3% Excellent → Excellent Stable Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+327%)	28.4% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+468%)	24.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+387%)	8.3% Fair Fair Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+65%)	—	—
EPS Growth YoY (%)	23.9% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	22.8% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	—	100.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	33.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	6.3% Fair Fair Year-over-year change in net income	22.2% Good Good Year-over-year change in net income	N/M	N/M	23.7% Good Good Year-over-year change in net income	—	—
FCF Growth YoY (%)	25.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	27.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	40.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-72.3% Weak Weak Year-over-year change in free cash flow	-4522.7% Weak Weak Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	25.8% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	24.7% Excellent Excellent Compound annual revenue growth over 3 years	20.0% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	21.8% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	-7.2% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-160%)	-15.3% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-227%)	-23.8% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-298%)	-32.5% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-370%)	-22.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-288%)	-4.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-136%)	—
Effective Tax Rate (%) (%)	0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	267.0% Weak ↑ Weak Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	5.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	3.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	-12.1% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-251%)	-16.4% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-305%)	-25.6% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-420%)	0.1% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-99%)	-5.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-167%)	-7.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-195%)	—
FCF Margin (%) (%)	-5.5% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-7.7% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-12.6% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-26.6% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-17.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-0.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.46x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.47x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.49x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-442.66x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	3.25x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	0.05x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-58.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-62.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-53.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	67.2% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-41.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-22.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-21.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-34.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-36.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-31.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-22.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-12.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	—	-145.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1071%)	0.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-99%)	-10.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-170%)	-51.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-440%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	-4.92x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-803%)	25.95x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+3607%)	1.52x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+118%)	0.65x Fair ↑ Fair Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-6%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.23x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-67%)	—
Interest Coverage (x)	-9.22x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-13.37x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-17.09x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-365.85x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-166.76x Weak Weak Operating income divided by interest expense Optimal: > 5x	-23.62x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$77.40M	$93.13M	$86.83M	$80.62M	$0.00	$6.56M	—
Debt / EBITDA (x)	-2.66x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.73x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.22x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.04x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.31x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$5.44	$5.24	$4.40	$3.47	$3.07	$3.17	—
Basic EPS, GAAP (USD)	$-0.54	$-0.71	$-0.92	$0.00	$-0.16	$-0.24	—
Free Cash Flow per Share (USD)	$-0.30	$-0.40	$-0.55	$-0.92	$-0.54	$-0.01	—
Book Value per Share (USD)	$-0.16	$0.05	$0.77	$1.68	$1.42	$0.48	$0.00
Tangible Book Value per Share (USD)	$-0.34	$-0.24	$0.43	$1.14	$0.81	$-0.10	$0.00
Basic Weighted Avg Shares (shares)	92.39M	75.04M	73.75M	72.79M	66.23M	59.12M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$41.78M	$60.20M	$108.70M	$100.70M	$124.26M	$1.11M	$-2.30K
LT Debt (USD)	$77.40M	$93.13M	$86.83M	$80.62M	$0.00	$6.56M	—
Total Equity (USD)	$-15.72M	$3.59M	$57.02M	$123.17M	$104.16M	$28.10M	$0.00

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$502.73M	$393.41M	$324.24M	$252.48M	$203.00M	$187.51M	—
Depreciation Expense (USD)	$6.94M	$6.29M	$5.87M	$4.41M	$3.34M	$3.18M	—
Net Income, GAAP (USD)	$-60.61M	$-64.66M	$-83.07M	$152.00K	$-10.93M	$-14.32M	—
Operating Cash Flow (USD)	$-24.59M	$-26.54M	$-36.31M	$-61.76M	$-32.68M	$508.00K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Oncology Institute, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TOI with peers